Want to see TNGX full AI Analyst Report?
TNGX Stock Chart & Stats
$24.77
$0.23(0.84%)
At close: 4:00 PM EDT
$24.77
$0.23(0.84%)
Day’s Range― - ―
52-Week Range$6.25 - $34.39
Previous CloseN/A
Volume1.26K
Average Volume (3M)2.23M
Market Cap
$3.80B
Enterprise Value$3.70K
Total Cash (Recent Filing)$1.01B
Total Debt (Recent Filing)$31.99M
Price to Earnings (P/E)―
Beta1.05
Next Earnings
Nov 10, 2026EPS Estimate
-0.35Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.85
Shares Outstanding168,610,370
10 Day Avg. Volume2,072,720
30 Day Avg. Volume2,226,620
Financial Highlights & Ratios
PEG Ratio0.38
Price to Book (P/B)2.97
Price to Sales (P/S)16.50
P/FCF Ratio-7.36
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$44.40Price Target Upside79.25% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering10
EPS Forecast (FY)-1.39
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Extended Funding RunwayThe large capital raise materially reduces near- to medium-term financing risk and gives Tango resources to fund pivotal trials, R&D and commercialization preparation without immediately relying on additional financing.
Promising Lead-Asset DataEncouraging early efficacy and tolerability support advancement of vopimetostat into a pivotal setting. Confirmation in later trials could strengthen the pipeline’s competitive position and create a path toward a commercial oncology product.
Low Financial LeverageModest leverage limits interest and refinancing pressure while the company funds clinical development. Combined with recently expanded equity capital, this provides greater financial flexibility to pursue its pipeline through later-stage trials.
Bears Say
Heavy Cash BurnPersistent, substantial cash consumption shows that operations are not self-funding and that Tango remains dependent on external capital. Even with an extended runway, continued development spending could require future financing.
Large Ongoing LossesThe cost structure remains far above current revenue, leaving the company distant from break-even. Sustained losses can erode shareholder value and make long-term returns dependent on successful clinical execution and eventual commercialization.
Revenue Concentration And DeclineDeclining and partnership-dependent revenue provides limited operating support while Tango remains pre-commercial. The absence of recurring product revenue makes financial performance sensitive to collaboration timing, milestones and trial outcomes.
Tango Therapeutics News
TNGX FAQ
What was Tango Therapeutics’s price range in the past 12 months?
Tango Therapeutics lowest stock price was $6.25 and its highest was $34.39 in the past 12 months.
What is Tango Therapeutics’s market cap?
Tango Therapeutics’s market cap is $3.80B.
When is Tango Therapeutics’s upcoming earnings report date?
Tango Therapeutics’s upcoming earnings report date is Nov 10, 2026 which is in 65 days.
How were Tango Therapeutics’s earnings last quarter?
Tango Therapeutics released its earnings results on Aug 11, 2026. The company reported -$0.37 earnings per share for the quarter, missing the consensus estimate of -$0.317 by -$0.053.
Is Tango Therapeutics overvalued?
According to Wall Street analysts Tango Therapeutics’s price is currently Undervalued.
Does Tango Therapeutics pay dividends?
Tango Therapeutics does not currently pay dividends.
What is Tango Therapeutics’s EPS estimate?
Tango Therapeutics’s EPS estimate is -0.35.
How many shares outstanding does Tango Therapeutics have?
Tango Therapeutics has 168,610,370 shares outstanding.
What happened to Tango Therapeutics’s price movement after its last earnings report?
Tango Therapeutics reported an EPS of -$0.37 in its last earnings report, missing expectations of -$0.317. Following the earnings report the stock price went down -4.807%.
Which hedge fund is a major shareholder of Tango Therapeutics?
Currently, no hedge funds are holding shares in TNGX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Tango Therapeutics Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$44.40 (79.25% Upside)
$44.40 (79.25% Upside)
Blogger Sentiment
Neutral
TNGX Sentiment 50%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Increased
By 2.5M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▼ 0.4%
Last 30 Days ▲ 11.0%
Last 30 Days ▲ 11.0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
229.72%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
351.42%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Tango Therapeutics
Tango Therapeutics, Inc. is a biotechnology firm dedicated to the research and development of innovative cancer treatments. Their primary therapeutic candidate, TNG908, is a synthetic lethal small molecule designed to inhibit protein arginine methyltransferase 5 (PRMT5). This compound is currently being advanced as a potential therapy for cancers characterized by methylthioadenosine phosphorylase (MTAP) deletions. Additionally, their pipeline includes an Ubiquitin-specific protease 1 (USP1) inhibitor targeting BRCA1 or BRCA2-mutant cancers, and a program known as 'Target 3' which addresses STK11-mutant cancers. Tango Therapeutics maintains a strategic alliance with Gilead Sciences, Inc., focused on the identification, advancement, and commercialization of a diverse array of cancer therapies. Established in 2017, the company's operations are headquartered in Cambridge, Massachusetts.
TNGX Stock 12 Month Forecast
Average Price Target
$44.40
▲(79.25% Upside)
Technical Analysis
Oruka Therapeutics
―
Immatics
―
ARS Pharmaceuticals
―
Prime Medicine, Inc.
―
Upstream Bio, Inc.
―
Ownership Overview
9.39% Insiders
7.85% Mutual Funds
70.47% Other Institutional Investors
0.24% Public Companies and Individual Investors